Financial Performance - The group's revenue for the three months ended June 30, 2023, was HKD 20,502,000, representing a 30.5% increase from HKD 15,696,000 in the same period of 2022[4] - Gross profit for the same period was HKD 10,071,000, up 27.8% from HKD 7,878,000 year-on-year[4] - The net profit attributable to the company's owners for the quarter was HKD 1,209,000, compared to HKD 1,079,000 in the previous year, reflecting an increase of 12.0%[4] - Basic and diluted earnings per share for the quarter were HKD 0.15, compared to HKD 0.13 in the same period last year, indicating a growth of 15.4%[4] - The total comprehensive income for the period was HKD 1,209,000, which includes a profit of HKD 1,079,000 from the previous year[5] - The group's revenue increased by approximately 31% from about HKD 15,700,000 for the three months ended June 30, 2022, to about HKD 20,500,000 for the three months ended June 30, 2023[28] - Gross profit for the three months ended June 30, 2023, was approximately HKD 10,100,000, an increase of about HKD 2,200,000 or 28% compared to approximately HKD 7,900,000 for the same period in 2022[29] - The gross margin slightly decreased from approximately 50.2% for the three months ended June 30, 2022, to approximately 49.1% for the three months ended June 30, 2023[29] - For the three months ended June 30, 2023, the group reported a profit of approximately HKD 1,200,000, an increase of about HKD 100,000 from approximately HKD 1,100,000 for the same period in 2022, primarily due to increased revenue offsetting higher administrative and operating expenses[33] Expenses and Dividends - Administrative and other operating expenses increased by approximately HKD 1,600,000 or 25% to about HKD 8,100,000 for the three months ended June 30, 2023, compared to approximately HKD 6,500,000 for the same period in 2022[30] - Research and development expenses amounted to approximately HKD 907,000 for the three months ended June 30, 2023, compared to HKD 619,000 for the same period in 2022[20] - The company declared dividends of HKD 3,200,000 during the quarter, an increase from HKD 2,400,000 declared in the same period last year[5] - The company did not declare any dividends for the three months ended June 30, 2023, consistent with the same period in 2022[22] - The board resolved not to declare any dividends for the three months ended June 30, 2023, consistent with the same period in 2022[34] Compliance and Governance - The financial statements for the quarter were unaudited but reviewed by the company's audit committee, ensuring a level of oversight[12] - The Audit Committee, established on March 1, 2018, consists of two independent non-executive directors and one non-executive director, ensuring compliance with GEM listing rules[52] - The Audit Committee has reviewed the unaudited condensed consolidated financial statements for the three months ended June 30, 2023, confirming compliance with applicable accounting standards and GEM listing regulations[52] - The company confirmed compliance with the "Code of Conduct" for securities trading as per GEM Listing Rules during the three months ended June 30, 2023[45] - The company adhered to all provisions of the corporate governance code, with minor deviations noted[49] Market and Strategic Outlook - The group primarily operates in Hong Kong, with all revenue generated from this region, indicating a focused market strategy[14] - The company continues to engage in the supply of medical instruments and solutions, which includes market trend analysis and after-sales services[7] - The company has established a joint venture to promote and realize future business development in the healthcare industry, focusing on autonomous mobile robotic solutions[26] - The company remains optimistic about the healthcare industry outlook due to the increasing elderly population and rising health awareness among Hong Kong citizens[26] Shareholder Information - As of June 30, 2023, B&A Success held approximately 568,028,001 shares, representing 71.00% of the company's total shares[39] - The total number of share options granted under the share option scheme as of June 30, 2023, was 21,460,000, with an exercise price of HKD 0.12 per share[42] - No share options were granted, exercised, forfeited, cancelled, or lapsed during the three months ended June 30, 2023[43] - The company did not purchase, sell, or redeem any of its listed securities during the three months ended June 30, 2023[44] - There were no interests or conflicts of interest reported by directors in any competing businesses as of June 30, 2023[47] Leadership - The role of the Chairman and CEO is currently held by Ms. Huang, who is responsible for formulating and guiding the overall strategy of the group[50] - The interest expense on lease liabilities was HKD 37,000 for the three months ended June 30, 2023, compared to HKD 34,000 for the same period in 2022[18] - The income tax expense for the three months ended June 30, 2023, was approximately HKD 400,000, compared to approximately HKD 200,000 for the same period in 2022[32]
君百延集团(08372) - 2024 Q1 - 季度财报